Cargando…

Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies

Enhancer of zeste homolog 2 (EZH2), an enzymatic subunit of PRC2 complex, plays an important role in tumor development and progression through its catalytic and noncatalytic activities. Overexpression or gain-of-function mutations of EZH2 have been significantly associated with tumor cell proliferat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mei, Husheng, Wu, Hong, Yang, Jing, Zhou, Bin, Wang, Aoli, Hu, Chen, Qi, Shuang, Jiang, Zongru, Zou, Fengming, Wang, Beilei, Liu, Feiyang, Chen, Yongfei, Wang, Wenchao, Liu, Jing, Liu, Qingsong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841011/ https://www.ncbi.nlm.nih.gov/pubmed/36642705 http://dx.doi.org/10.1038/s41392-022-01240-3

Ejemplares similares

Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus
por: Wang, Junjie, et al.
Publicado: (2023)

Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy
por: Hu, Chen, et al.
Publicado: (2023)

Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode
por: Hu, Chen, et al.
Publicado: (2017)

Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities
por: Hu, Chen, et al.
Publicado: (2022)

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model
por: Wu, Hong, et al.
Publicado: (2017)

Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)
por: Liu, Feiyang, et al.
Publicado: (2016)

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma
por: Wu, Hong, et al.
Publicado: (2014)

Pharmacological inhibiting STAT5 for the treatment of FLT3‐ITD‐positive acute myeloid leukemia with triciribine phosphate monohydrate
por: Wu, Hong, et al.
Publicado: (2023)

Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent
por: Jiang, Zongru, et al.
Publicado: (2020)

Discovery of a highly potent and selective Bruton’s tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma
por: Liu, Juan, et al.
Publicado: (2020)

Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib‐induced KIT mutations in gastrointestinal stromal tumours
por: Liu, Juan, et al.
Publicado: (2022)

Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs)
por: Yu, Kailin, et al.
Publicado: (2017)

Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia
por: Hu, Chen, et al.
Publicado: (2021)

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
por: Wu, Hong, et al.
Publicado: (2015)

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances
por: Liu, Xiaochuan, et al.
Publicado: (2016)

Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia
por: Wang, Aoli, et al.
Publicado: (2020)

An overview of kinase downregulators and recent advances in discovery approaches
por: Wang, Beilei, et al.
Publicado: (2021)

Identification and Characterization of an Irreversible Inhibitor of CDK2
por: Anscombe, Elizabeth, et al.
Publicado: (2015)

Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies
por: Liu, Xiaochuan, et al.
Publicado: (2016)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

PEG-Bottlebrush Stabilizer-Based Worm-like Nanocrystal Micelles with Long-Circulating and Controlled Release for Delivery of a BCR-ABL Inhibitor against Chronic Myeloid Leukemia (CML)
por: Liang, Huamin, et al.
Publicado: (2022)

Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences
por: Wang, Aoli, et al.
Publicado: (2020)

Health Tract No. 337: Architects
Publicado: (1868)

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation
por: Wang, Aoli, et al.
Publicado: (2016)

337 Innovation Opportunities within Lymphedema
por: Plona, Zachary, et al.
Publicado: (2022)

CDK12: A Potent Target and Biomarker for Human Cancer Therapy
por: Liang, Shujing, et al.
Publicado: (2020)

Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13
por: Yang, Jianzhang, et al.
Publicado: (2022)

Dependency of the Spindle Assembly Checkpoint on Cdk1 Renders the Anaphase Transition Irreversible
por: Rattani, Ahmed, et al.
Publicado: (2014)

Product, building, and infrastructure material stocks dataset for 337 Chinese cities between 1978 and 2020
por: Li, Xiang, et al.
Publicado: (2023)

MEDB-81. Combined inhibition of CDK11 and EZH2 results in regression of MYC-amplified medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

miR-337-3p inhibits gastric tumor metastasis by targeting ARHGAP10
por: Wang, Zishu, et al.
Publicado: (2020)

Identification of an irreversible PPARγ antagonist with potent anticancer activity
por: Peng, Youyi, et al.
Publicado: (2020)

Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors
por: Liu, Feiyang, et al.
Publicado: (2019)

MicroRNA-337 inhibits colorectal cancer progression by directly targeting KRAS and suppressing the AKT and ERK pathways
por: Liu, Xuerong, et al.
Publicado: (2022)

Small molecules targeting Pin1 as potent anticancer drugs
por: Zhang, Jing, et al.
Publicado: (2023)

337 Allergic Disorders Prevented by Helicobacter Pylori Colonization
por: Herbarth, Olf, et al.
Publicado: (2012)

Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2
por: Xue, Yiying, et al.
Publicado: (2023)

Dipeptide-Derived Alkynes as Potent and Selective Irreversible Inhibitors of Cysteine Cathepsins
por: Behring, Lydia, et al.
Publicado: (2023)

An iridium(iii)-based irreversible protein–protein interaction inhibitor of BRD4 as a potent anticancer agent
por: Zhong, Hai-Jing, et al.
Publicado: (2015)

Modeling the prevalent germline TP53 R337H mutation in mouse
por: Park, Ji-Hoon, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aivfhvko34t96sk0cg9ter40rq